BG Medicine, Boston Scientific Study Galectin-3 for CRT | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BG Medicine today announced a collaboration with Boston Scientific to study whether galectin-3 can be used to screen patients for cardiac-resynchronization therapy.

Data for their effort will come from the MADIT-CRT study, the world's largest randomized study of New York Heart Association Class I and II patients. The study involves more than 1,800 patients enrolled in 110 centers worldwide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.